About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Immune Disorder HSCT Protocol

NCT01821781·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Washington University School of Medicine

Age

0–21

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

\</= 28 years of age
Performance status \>/= 40
DLCO \>/= 40%
LVEF \>/=40% or LVSF \>/=26%
Serum creatinine \< 2x ULN
Liver enzymes \</= 5x ULN
Negative pregnancy test
Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 5-6/6 matched unrelated UCB, 7-8/8 matched unrelated BM, double cord)

You may not be if

Known diagnosis of HIV I/II
Pregnant or breastfeeding
Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting alemtuzumab
Uncontrolled viral infection within 1 week prior to starting alemtuzumab

The record

StatusCompleted

PhasePhase 2

Taking part28

StartedApr 2013

UpdatedOct 27, 2026

Conditions

Immune Deficiency Disorders Severe Combined Immunodeficiency Chronic Granulomatous Disease X-linked Agammaglobulinemia Wiskott-Aldrich Syndrome+9

Where1

Washington University
St Louis, Missouri, United States

Clareo Health | Immune Disorder HSCT Protocol